Blog
RSS FeedPosted by Michael Wonder on 13 Jun 2019
Aimmune wins over ICER for peanut allergy product
12 June 2019 - Analysts predict blockbuster status for first-in-class. ...
Posted by Michael Wonder on 08 Jun 2019
ICER to assess treatments for acute migraine
7 June 2019 - Report will be subject of Midwest CEPAC meeting in January 2020; open input now being accepted until ...
Posted by Michael Wonder on 28 May 2019
ICER’s assessment highlights the risk-benefit tradeoffs of investigational treatments for peanut allergy
28 May 2019 - To achieve commonly cited thresholds for cost-effectiveness, the annual price would need to be between $4,800-$7,200 for ...
Posted by Michael Wonder on 22 May 2019
ICER releases draft evidence report on treatments for Duchenne muscular dystrophy
22 May 2019 - Public comment period now open until June 18, 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 13 May 2019
Congress should revive the Office of Technology Assessment
13 May 2019 - In recent decades, the U.S. economy and society have been propelled forward by a boom in science ...
Posted by Michael Wonder on 10 May 2019
Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds
9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting. ...
Posted by Michael Wonder on 03 May 2019
ICER publishes evidence report on the use of siponimod to treat secondary progressive multiple sclerosis
2 May 2019 - Midwest CEPAC to deliberate on the treatment’s clinical effectiveness and other potential benefits during its May ...
Posted by Michael Wonder on 02 May 2019
ICER posts draft scoping document for the assessment of treatments for type 2 diabetes mellitus
2 May 2019 - Document open to public comment until 22 May 2019. ...
Posted by Michael Wonder on 23 Apr 2019
ICER's growing impact on drug pricing and reimbursement
17 April 2019 - The Institute for Clinical and Economic Review is sometimes called America's `NICE,’ referring to the National ...
Posted by Michael Wonder on 11 Apr 2019
The perils of value based pricing for prescription drugs
11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019. ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review to assess treatments for type 2 diabetes mellitus
11 April 2019 - Report will be subject of New England CEPAC meeting in November 2019; open Input now being ...
Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 03 Apr 2019
Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer
2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...